There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Collegium Pharmaceutical (COLL – Research Report) and Hologic (HOLX – Research Report) with bullish sentiments.
Collegium Pharmaceutical (COLL)
Needham analyst Serge Belanger maintained a Buy rating on Collegium Pharmaceutical today and set a price target of $40.00. The company’s shares closed last Thursday at $33.47, close to its 52-week high of $34.96.
According to TipRanks.com, Belanger is a 2-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Collegium Pharmaceutical with a $38.00 average price target.
See today’s best-performing stocks on TipRanks >>
Hologic (HOLX)
In a report released today, Michael Matson from Needham reiterated a Buy rating on Hologic, with a price target of $90.00. The company’s shares closed last Thursday at $74.41.
According to TipRanks.com, Matson is a 1-star analyst with an average return of
Hologic has an analyst consensus of Moderate Buy, with a price target consensus of $81.30, which is a 9.2% upside from current levels. In a report issued on January 23, Argus Research also maintained a Buy rating on the stock with a $89.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on COLL:
- Collegium Pharmaceutical management to meet virtually with Needham
- Collegium Pharmaceutical price target raised to $37 from $31 at Truist
- Collegium Pharmaceutical downgraded to Hold from Buy at Jefferies
- Collegium Pharmaceutical board authorizes $150M share repurchase program
- Collegium Pharmaceutical sees 2024 product revenue $580M-$595M
